Trovagene, Inc. announced the publication of study results in Clinical Cancer Research, demonstrating the analytical and clinical performance of Trovera urine and blood liquid biopsy tests to quantitatively assess KRAS mutations in patients with diverse advanced cancers.  This data was also featured as a presentation at the 2017 Gastrointestinal Cancers Symposium on January 21st in San Francisco, CA. The data demonstrate the clinical utility of Trovagene's proprietary mutation-enrichment technology to detect and quantitate KRAS mutations in urine and plasma from patients with advanced cancers. This was a blinded study with prospectively collected liquid biopsy samples, and archived tissue samples with known KRAS mutation status, from 71 patients with diverse advanced cancers. Overall KRAS concordance between ctDNA and tissue specimens was 89% with urine sample volume of 90-110 mL. In a subset of patients with simultaneous collection of plasma, data demonstrated excellent concordance of 94% with tumor tissue. The dynamics of KRASG12/G13 mutant copies of ctDNA from urine and plasma corresponded with patient response to therapy.